Gabrielle F.

☆Residente de oncologia ♡

[MV Chandrakanth @ChandrakanthMv]

Why Add Celecoxib to Immunotherapy?

The PICC-2 trial explored whether blocking the COX-2/PGE₂ pathway could enhance the activity of PD-1 blockade in dMMR/MSI-H locally advanced colorectal cancer.

By reducing immune suppression within the tumor microenvironment, celecoxib may help T cells eliminate residual cancer more effectively.

Pathological complete response improved from 69% to 89% with the addition of celecoxib.

The combination achieved this benefit without increasing treatment-related toxicity.

A promising strategy that warrants further validation, but adds an intriguing layer to neoadjuvant immunotherapy.

[Erman Akkus @Erman_Akkus]

🔵PDL-1 (CPS) in gastroesophageal cancers
🔬FDA and NCCN

#cancer #oncology #MedX #GI @OncoAlert

[Rohit Malde @roxboxfix]

1st Line EGFR + mNSCLC Rx options
Thinking beyond Flaura

Resistance Mechanisms

2nd Line Rx Options

Sequencing Evolving
More options evolving

[JAMA @JAMA_current]

🔖 Bookmark now, reference later: Management of #ThyroidCancer increasingly reflects #tumor size, #disease extent, and #molecular profile.

This #JAMAReview indicates that observation without surgical resection can be considered for microcarcinomas ≤1 cm, while surgery with or without #RadioactiveIodine is curative in most cases for tumors >1 cm with or without lymph node metastases.

➡️ Save this Review to your citation manager and reference it in future research: https://t.co/aSFQfwJdvO

[Dr Amol Akhade @SuyogCancer]

Nice Infographics to Show
1-mechanism of resistance of ADCs used in Breast Cancer
2-structural details of Newer ADC being studied in Breast cancer
3- Timeline for approval of All ADCs by USA FDA in Breast cancer till date.

Useful for quick reference .

[Andrea Necchi, MD, FASCO @AndreaNecchi]

Cystectomy Can Be Spared in Selected Patients with Muscle-invasive Bladder Cancer and Complete Response Following Neoadjuvant Therapy - @EUplatinum @OncoAlert @urotoday #cCR @IBCG_BladderCA #Milancriteria @SanRaffaeleMI @MyUniSR https://t.co/1hFuIT0QK4

[Rohit Malde @roxboxfix]

Capecitabine + Oxaliplatin
Chemo Regimen

COLORECTAL cancers

Doses
Indications
Toxicity and Grading
Dose Reductions and Stopping Rules

A simple Glance for Oncologists in Clinics

[Karamvir Yadav @K_Yadavir]

EAU 2026 Prostate Cancer Guidelines are here.

Key updates:
✅ Early salvage RT for BCR
✅ PSMA PET as preferred imaging
✅ ADT alone is no longer enough for most mHSPC patients
✅ Molecular testing guides precision therapy
✅ Triplet therapy for appropriate patients
✅ Prostate RT remains important in low-volume metastatic disease

Personalized, biology-driven treatment is now the standard.

#ProstateCancer #EAU26 #GUOnc #UroOnc #MedTwitter #Oncology #PrecisionOncology @oncodaily

[Erman Akkus @Erman_Akkus]

Expanding the path to cure - a narrative review on optimizing multimodality sequencing in HCC - Cancer Treatment Reviews https://t.co/A4QmunIjxM

[Daisuke Kotani, MD, Ph.D 小谷 大輔 @DaisukeKotani]

Position statement on ADCs in solid tumors
The recent pivotal studies & key ongoing studies on ADCs are summarized in Table 1 & 2.
🔗https://t.co/Zp6DWW9Cb8
@ESMO_Open @OncoAlert

[Erman Akkus @Erman_Akkus]

🔴Cancer-associated thrombosis in GI cancers

#cancer #oncology #MedX #GI @OncoAlert

[Benlazar S M A @smbenlazar]

Newly diagnosed acute myeloid leukemia in Fit patients: 2026 treatment algorithms https://t.co/wq2Cbwlk9Q #leusm @n_gangat

[Dr Rishabh Jain @DrRishabhOnco]

🚨 New @ASCO guideline on breast cancer surveillance after curative treatment

The biggest change: follow-up should be risk-adapted, not one-size-fits-all.

Clinical follow-up

🔹 Low risk: annually
🔹 Intermediate risk: every 6–12 months
🔹 High risk: every 3–6 months
🔹 Virtual visits are acceptable

What should be done

✅ History and physical examination
✅ Surveillance mammography
✅ Prompt evaluation of new symptoms

What should NOT be done routinely in asymptomatic patients

❌ CT or PET-CT
❌ Bone scan
❌ Chest X-ray or liver ultrasound
❌ CBC or chemistry panels
❌ CEA, CA 15-3 or CA 27.29
❌ ctDNA surveillance outside clinical trials

Important de-escalation

For selected low-risk patients aged ≥50 years who remain recurrence-free 3 years after breast-conserving surgery, mammography every 1–2 years may be reasonable instead of annual imaging.

Clinical takeaway
More surveillance does not necessarily improve outcomes.

Follow recurrence risk, symptoms and evidence, not anxiety.

Will this change your follow-up practice?

@oncoalert #BreastCancer #ASCOGuidelines

[Enrique Grande @drenriquegrande]

⚡️ Updated NICE 2026 guideline on kidney cancer: a comprehensive pathway from suspicion to risk-adapted treatment and follow-up.

87% of stage 1a RCC in the UK is diagnosed incidentally. A reminder of how challenging early detection remains in everyday clinical practice.

https://t.co/O6xWOoleIv

#KidneyCancer @OncoAlert

[Journal of Clinical Oncology @JCO_ASCO]

Reducing or Omitting Dexamethasone With NEPA and Olanzapine for Prevention of Chemotherapy-Induced Nausea and Vomiting in Highly Emetogenic Chemotherapy: A Randomized Non-inferiority Phase III Trial.

Read the full article. https://t.co/1ViN8LNj87

[Medscape Oncology @MedscapeOnc]

📢 Registration is now open for the Acute Leukemia Forum! 🔬Join outstanding faculty as we explore the latest advances in acute leukemia research, treatment strategies, and patient care. Secure your spot, connect with colleagues, and be part of the conversations shaping the future. 🚨 Register today! ➡️ https://t.co/HvPXYww57A

[MV Chandrakanth @ChandrakanthMv]

DENOSUMAB DE-ESCALATION

For years, monthly denosumab has been the standard for patients with bone metastases.

But after initial therapy, do patients really need treatment every 4 weeks indefinitely?

REDUSE 96/12 addressed this question in 1,380 patients with breast cancer or mCRPC and bone metastases.

After 4 initial monthly doses:

• Every 12-week dosing achieved non-inferior skeletal protection • Time to first symptomatic skeletal event: 56.6 vs 56.5 months HR 1.02

Importantly:

• Hypocalcemia decreased from 46% → 30% • Osteonecrosis of the jaw decreased from 8.5% → 6.9%

The message is simple:

Less frequent treatment may preserve efficacy while reducing toxicity and treatment burden.

A potentially practice-changing maintenance strategy for bone metastases.

#MVOnco #ASCO2026 #Denosumab #BoneMetastases #BreastCancer #mCRPC #SupportiveCare #BoneHealth #Oncology #MedTwitter #OncTwitter

[Erman Akkus @Erman_Akkus]

🟩GCSF use in oncology
NCCN guideline summary

#cancer #oncology #MedX #blood @OncoAlert @weoncologists @realbowtiedoc @crisbergerot

[Erman Akkus @Erman_Akkus]

🟦Nausea-Vomiting Prevention
ESMO-MASCC 2023 guideline summary

#cancer #oncology #MedX @OncoAlert @CancerCareMASCC

[Sociedad Mexicana de Oncología, A.C. @SMEOMX]

🚨 Mañana es nuestra Sesión Académica Virtual SMeO sobre CPCNP HER2m.

📅 11 de junio
🕗 20:00 a 21:30 hrs

Consulta el programa académico y regístrate.

🔗 Registro disponible en nuestra pagina web: https://t.co/4gQ5rlnLQH./eventos

#SMeO #Oncología #OncologíaMX #CáncerDePulmón #EducaciónMédicaContinua